PedAM

Pediatric Disease Annotations & Medicines


	leukocytosis

Disease ID	1929
Disease	leukocytosis
Definition	A transient increase in the number of leukocytes in a body fluid.
Synonym	increased blood leukocyte number leucocytosis leucocytosis (finding) leucocytosis, nos leukocytoses leukocytosis (disorder) leukocytosis (leucocytosis) leukocytosis [disease/finding] leukocytosis nos leukocytosis, nos leukocytosis, unspecified
UMLS	C0023518
MeSH	D007964
SNOMED-CT	SNOMEDCT_US_2016_09_01:111583006
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:71) C0002871 \| anemia \| 13 C0032285 \| pneumonia \| 5 C0040034 \| thrombocytopenia \| 5 C0836924 \| thrombocytosis \| 4 C0040053 \| thrombosis \| 3 C0015230 \| rash \| 3 C0023418 \| leukemia \| 3 C0476089 \| endometrial ca \| 3 C0024312 \| lymphopenia \| 2 C0007642 \| cellulitis \| 2 C0007847 \| cervical cancer \| 2 C0242379 \| lung cancer \| 2 C0002871 \| anaemia \| 2 C0476089 \| endometrial carcinoma \| 2 C0302592 \| cervical ca \| 2 C0085669 \| acute leukemia \| 2 C0153446 \| anal cancer \| 2 C0003615 \| appendicitis \| 2 C0027022 \| myeloproliferative disorders \| 1 C0023269 \| leiomyosarcoma \| 1 C0476089 \| endometrial cancer \| 1 C0042373 \| vascular disease \| 1 C0015231 \| roseola infantum \| 1 C0025289 \| meningitis \| 1 C0041296 \| tuberculosis \| 1 C0027051 \| myocardial infarct \| 1 C0085576 \| microcytic anemia \| 1 C0020437 \| hypercalcemia \| 1 C0085693 \| acute appendicitis \| 1 C0032461 \| polycythemia \| 1 C0004623 \| bacterial infection \| 1 C0007222 \| cardiovascular disease \| 1 C0007131 \| nsclc \| 1 C0162429 \| malnourished \| 1 C0002965 \| unstable angina \| 1 C0009402 \| colorectal cancer \| 1 C0027051 \| myocardial infarction \| 1 C0020443 \| hypercholesterolemia \| 1 C0041948 \| uremia \| 1 C0221406 \| cushing's disease \| 1 C0034063 \| pulmonary edema \| 1 C0024110 \| lung abscess \| 1 C0011991 \| diarrhea \| 1 C0162316 \| iron deficiency anemia \| 1 C0024530 \| malaria \| 1 C1145670 \| respiratory failure \| 1 C0003864 \| arthritis \| 1 C0007115 \| thyroid ca \| 1 C0023530 \| leucopenia \| 1 C0006017 \| pertussis \| 1 C0271901 \| microcytic hypochromic anemia \| 1 C0027022 \| myeloproliferative disorder \| 1 C0015231 \| roseola \| 1 C0021400 \| influenza \| 1 C0020455 \| hypergammaglobulinemia \| 1 C0025295 \| pneumococcal meningitis \| 1 C0002448 \| ameloblastoma \| 1 C0027947 \| neutropenia \| 1 C0032463 \| polycythemia vera \| 1 C0010692 \| bladder inflammation \| 1 C0023443 \| hairy cell leukemia \| 1 C0023530 \| leukopenia \| 1 C0235974 \| pancreatic cancer \| 1 C0001815 \| myelofibrosis \| 1 C0549473 \| thyroid carcinoma \| 1 C0238461 \| anaplastic thyroid carcinoma \| 1 C0007113 \| rectal cancer \| 1 C0677886 \| epithelial ovarian carcinoma \| 1 C0002965 \| unstable angina pectoris \| 1 C0948265 \| metabolic syndrome \| 1 C0007138 \| urothelial carcinoma \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:2) IL1B \| 3553 \| CTD_human CSF3R \| 1441 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1929
Disease	leukocytosis
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:71) HP:0001880 \| Eosinophilia \| 30 HP:0100827 \| Lymphocytosis \| 20 HP:0001945 \| Fever \| 15 HP:0001903 \| Anemia \| 15 HP:0012531 \| Pain \| 11 HP:0012311 \| High blood monocyte number \| 8 HP:0003565 \| Elevated sedimentation rate \| 6 HP:0002090 \| Pneumonia \| 5 HP:0001873 \| Low platelet count \| 5 HP:0030731 \| Carcinoma \| 4 HP:0002664 \| Neoplasia \| 4 HP:0001894 \| Thrombocytosis \| 4 HP:0002789 \| Increased respiratory rate or depth of breathing \| 3 HP:0100806 \| Sepsis \| 3 HP:0001909 \| Leukemia \| 3 HP:0002488 \| Acute leukemias \| 2 HP:0011134 \| Mild fever \| 2 HP:0010783 \| Erythema \| 2 HP:0002027 \| Abdominal pain \| 2 HP:0002910 \| Elevated transaminases \| 2 HP:0001888 \| Lymphocytopenia \| 2 HP:0011227 \| Elevated C-reactive protein level \| 2 HP:0001744 \| Splenomegaly \| 2 HP:0002716 \| Lymph node hyperplasia \| 2 HP:0012114 \| Endometrial carcinoma \| 2 HP:0100658 \| Bacterial infection of skin \| 2 HP:0001941 \| acidemia \| 2 HP:0001901 \| Abnormally shaped erythrocytes \| 2 HP:0001944 \| Dehydration \| 1 HP:0011974 \| Myelofibrosis \| 1 HP:0001082 \| Cholecystitis \| 1 HP:0000969 \| Dropsy \| 1 HP:0003124 \| Elevated serum cholesterol \| 1 HP:0002344 \| Progressive neurologic deterioration \| 1 HP:0001875 \| Neutropenia \| 1 HP:0001681 \| Angina pectoris \| 1 HP:0002094 \| Dyspnea \| 1 HP:0001891 \| Iron-deficiency anemia \| 1 HP:0003072 \| Hypercalcemia \| 1 HP:0100598 \| Pulmonary oedema \| 1 HP:0010702 \| Hypergammaglobulinaemia \| 1 HP:0002890 \| Thyroid carcinoma \| 1 HP:0005547 \| Myeloproliferative disorder \| 1 HP:0002014 \| Diarrhea \| 1 HP:0011106 \| Depleted blood volume \| 1 HP:0200058 \| Angiosarcoma \| 1 HP:0002045 \| Abnormally low body temperature \| 1 HP:0003259 \| Increased serum creatinine \| 1 HP:0000988 \| Exanthem \| 1 HP:0100243 \| Leiomyosarcoma \| 1 HP:0001981 \| Schistocytosis \| 1 HP:0001919 \| Acute renal failure \| 1 HP:0001935 \| Microcytic anemia \| 1 HP:0001907 \| Thromboembolic disease \| 1 HP:0002900 \| Hypokalemia \| 1 HP:0001824 \| Weight loss \| 1 HP:0002902 \| Hyponatremia \| 1 HP:0011779 \| Anaplastic thyroid carcinoma \| 1 HP:0001923 \| Reticulocytosis \| 1 HP:0002878 \| Respiratory failure \| 1 HP:0001882 \| Decreased blood leukocyte number \| 1 HP:0001658 \| Myocardial infarction \| 1 HP:0002093 \| progressive respiratory failure \| 1 HP:0001895 \| Normochromic anemia \| 1 HP:0000967 \| Petechiae \| 1 HP:0000752 \| Hyperactive behavior \| 1 HP:0001942 \| Metabolic acidosis \| 1 HP:0002829 \| Arthralgias \| 1 HP:0001369 \| Arthritis \| 1 HP:0001287 \| Meningitis \| 1 HP:0002894 \| Neoplasia of the pancreas \| 1

Disease ID	1929
Disease	leukocytosis
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:18)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0023518	arsenic trioxide	C006632	1327-53-3	leukocytosis	MESH:D007964	marker/mechanism	11007035
C0023518	azithromycin	D017963	83905-01-5	leukocytosis	MESH:D007964	therapeutic	21195124
C0023518	carbamazepine	D002220	298-46-4	leukocytosis	MESH:D007964	marker/mechanism	2327680
C0023518	chloramphenicol	D002701	56-75-7	leukocytosis	MESH:D007964	marker/mechanism	4800729
C0023518	ciprofloxacin	D002939	85721-33-1	leukocytosis	MESH:D007964	marker/mechanism	11476450
C0023518	ciprofloxacin	D002939	85721-33-1	leukocytosis	MESH:D007964	therapeutic	19401694
C0023518	clozapine	D003024	5786-21-0	leukocytosis	MESH:D007964	marker/mechanism	11307364
C0023518	erythromycin	D004917	114-07-8	leukocytosis	MESH:D007964	marker/mechanism	8629881
C0023518	hydroxyurea	D006918	127-07-1	leukocytosis	MESH:D007964	therapeutic	17136541
C0023518	indinavir	D019469	150378-17-9	leukocytosis	MESH:D007964	marker/mechanism	12571522
C0023518	indomethacin	D007213	53-86-1	leukocytosis	MESH:D007964	therapeutic	16537180
C0023518	propylthiouracil	D011441	51-52-5	leukocytosis	MESH:D007964	marker/mechanism	1806466
C0023518	rifampin	D012293	13292-46-1	leukocytosis	MESH:D007964	marker/mechanism	11837753
C0023518	rofecoxib	C116926	-	leukocytosis	MESH:D007964	marker/mechanism	15892770
C0023518	thalidomide	D013792	50-35-1	leukocytosis	MESH:D007964	marker/mechanism	11972510
C0023518	theophylline	D013806	58-55-9	leukocytosis	MESH:D007964	marker/mechanism	20940509
C0023518	tretinoin	D014212	302-79-4	leukocytosis	MESH:D007964	marker/mechanism	10609785
C0023518	zafirlukast	C062735	107753-78-6	leukocytosis	MESH:D007964	marker/mechanism	18489783

FDA approved drug and dosage information(Total Drugs:7)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D007964	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D007964	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D007964	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D007964	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D007964	vioxx	rofecoxib	12.5MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D007964	vioxx	rofecoxib	12.5MG/5ML	SUSPENSION;ORAL	Discontinued	None	No	No
MESH:D007964	vioxx	rofecoxib	12.5MG	TABLET; ORAL	Discontinued	None	No	No

FDA labeling changes(Total Drugs:7)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D007964	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D007964	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D007964	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D007964	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D007964	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'
MESH:D007964	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'
MESH:D007964	08/19/2004	vioxx	rofecoxib	Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004.	Labeling	B	-	-	-	Merck	02/18/2004	FALSE'

Web
Analytics